In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents

Journal of Clinical Microbiology

Volumn 37, Issue 3, 1999, Pages 870-872

  Pfaller, M A ^a   Messer, S A ^a   Gee, S ^b   Joly, S ^c   Pujol, C ^c   Sullivan, D J ^b   Coleman, D C ^b   Soll, D R ^c  

^a UNIVERSITY OF IOWA   (United States)

^b DUBLIN DENTAL UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANDIDA DUBLINIENSIS; CANDIDIASIS; FUNGUS IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

CANDIDA DUBLINIENSIS; FUNGI;

EID: 0033036973     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.3.870-872.1999     Document Type: Article

References (19)

1. Birkandi, J., R. San Millan, M. D. Moragnes, G. Cebas, M. Clarke, D. C. Coleman, D. J. Sullivan, G. Quindos, and J. Ponton. 1998. Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes. J. Clin. Microbiol. 36:2428-2433.
2. Coleman, D. C., D. J. Sullivan, D. E. Bennett, G. P. Moran, H. J. Barry, and D. B. Shanley. 1997. Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 11:557-567.
3. Joly, S., et al. 1998. Unpublished observations.
4. Marco, F., M. A. Pfaller, S. Messer, and R. N. Jones. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42:161-163.
5. Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida spp. Diagn. Microbiol. Infect. Dis., in press.
6. Moran, G. P., D. J. Sullivan, M. C. Herman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41: 617-623.
7. Moran, G. P., D. Sanglard, S. M. Donnelly, D. B. Shanley, D. J. Sullivan, and D. C. Coleman. 1998. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42:1819-1830.
8. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
10. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, R. J. Hollis, and S. A. Messer for the SENTRY Participant Group. 1998. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program. J. Clin. Microbiol. 36:1886-1889.
11. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1998. In vitro susceptibilities of Candida blood-stream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. 42:3242-3244.
12. Pinjon, E., D. Sullivan, I. Salkin, D. Shantey, and D. Coleman. 1998. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J. Clin. Microbiol. 36:2093-2095.
13. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
14. Schoofs, A., F. C. Odds, R. Colebunders, M. Leven, and H. Goosens. 1997. Use of specialized isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur. J. Clin. Infect. Dis. 16:296-300.
15. Sullivan, D., and D. Coleman. 1998. Candida dubliniensis: characteristics and identification. J. Clin. Microbiol. 36:329-334.
16. Sullivan, D. J., T. J. Westerneng, K. A. Haynes, D. E. Bennett, and D. C. Coleman. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidiasis in HIV-infected individuals. Microbiology 141:1507-1521.
17. Sullivan, D. J., K. Haynes, J. Bille, P. Boerlin, L. Rodero, S. Lloyd, M. Henman, and D. Coleman. 1997. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 35:960-964.
18. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.
19. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.